Table 2.
ADAs and serum concentrations of adalimumab (A) and ozoralizumab (B) in the continued group and the switched group at the end of the study.
| A | ||
|---|---|---|
| Group | ADAs against adalimumab (Log titer) | Serum adalimumab concentration (ng/ml) |
| Continued group | Pos (2.86) | BLQ |
| Pos (3.34) | BLQ | |
| Pos (2.39) | BLQ | |
| Pos (0.477) | 10.9 | |
| Pos (1.43) | BLQ | |
| Pos (2.39) | BLQ | |
| Pos (2.86) | BLQ | |
| Pos (2.86) | BLQ | |
| Pos (3.34) | BLQ | |
| Neg | 90.5 | |
| Pos (2.86) | BLQ | |
| Pos (2.86) | BLQ | |
| Pos (3.34) | BLQ | |
| Switched group | Pos (0.954) | BLQ |
| Pos (2.39) | BLQ | |
| Pos (1.43) | BLQ | |
| Pos (1.91) | BLQ | |
| Pos (1.91) | BLQ | |
| Pos (1.91) | BLQ | |
| Pos (1.91) | BLQ | |
| Pos (1.91) | BLQ | |
| Pos (1.43) | BLQ | |
| Pos (1.91) | BLQ | |
| B | ||
| Group | ADAs against ozoralizumab (Log titer) | Serum ozoralizumab concentration (ng/ml) |
| Switched group | Neg | 538 |
| Neg | 170 | |
| Neg | 1690 | |
| Neg | 101 | |
| Neg | 15.4 | |
| Pos (<0.477) | BLQ | |
| Neg | 161 | |
| Neg | 12.1 | |
| Neg | 14.1 | |
| Pos (<0.477) | BLQ |
Pos, positive; Neg, negative (not above the screening cut-off point); BLQ, below the lower limit of quantification (<10.0 ng/mL).